Novo Nordisk Rises Nearly 2% in Pre-Market Trading Amid Aggressive Expansion Plans

Gelonghui May 23 | Novo Nordisk (NVO.US) rose 1.85% in pre-market trading to $136.51. At the "2024 Novo Nordisk Headquarters Media Briefing" held on May 21, Henrik Wulff, Executive Vice President of Novo Nordisk and head of Product Supply, Quality, and IT, stated, "We are continuously increasing our investment across the entire industrial chain to meet market demands for both current and future products. We are focused on delivering high-quality products to patients worldwide in an efficient and environmentally sustainable manner. Several key capacity expansion projects are currently underway at full speed across global production facilities."